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Severe Pre-Eclampsia in the Setting of COVID-19
Case Report of Three Patients in Detroit, Michigan
Amneet Sran, MD, Tra V. Pham, MD, and Quoc V. Le, MD.
Department of Obstetrics and Gynecology. Henry Ford Health System, Detroit, Michigan

Summary
• The current pandemic caused by severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) results in coronavirus disease 2019 (COVID-19).
• The World Health Organization (WHO) reported 2,724,809 confirmed cases of
COVID-19 globally including 187,847 deaths as of April 25, 2020. [1]
• In the United States, there have been 860,772 confirmed COVID-19 cases including
44,053 deaths. [1]
• COVID-19 can mimic other diseases, such as preeclampsia, which is known to cause
liver, respiratory, and renal impairment
• Common symptoms of COVID-19 include fever (87.9%), dry cough (67.7%), sputum
(33.4%), shortness of breath (18.6%), and headache (13.6%). [2]
• Laboratory abnormalities include thrombocytopenia (36.2%), elevated liver enzymes
(21.3-22.2%), and elevated lactate dehydrogenase (41.0%), similar to preeclampsia.
• Diagnostic criteria of severe pre-eclampsia [3]:
1. Severe range blood pressures with systolic blood pressure above 160 mmHg or
diastolic blood pressure above 110 mmHg
2. Thrombocytopenia less than 100,000 109/L
3. Elevated liver enzymes two times the upper limit of normal
4. Creatinine above 1.1 mg/dL or doubling of serum creatinine in the absence of renal
disease
5. Persistent neurologic symptoms such as headache or visual abnormalities
6. Pulmonary edema
• This case series discusses three patients who presented to our institution with elevated
blood pressures and respiratory complaints to demonstrate the complexity of
delineating the diagnoses.

Case 1. Severe Pre-Eclampsia
An 18 year old gravida 1 female presented at 36 weeks 5 days with worsening dyspnea,
cough, subjective fevers, and persistent headache. She previously presented at 33 weeks with
respiratory symptoms, tested for COVID-19, and discharged home with standard COVID
precautions. Her COVID-19 swab resulted positive two days later and she was notified. Upon
re-presentation, she complained of worsening respiratory symptoms, unresolved headache
despite acetaminophen, and right upper quadrant pain for one week. Her heart rate was 122
beats/min, respiratory rate 22 breaths/min, temperature 37oC, blood pressure 178/128 mmHg.
Over a short course, her oxygen saturation (SpO2) dropped to 92%, and she required
oxygen supplementation with nasal cannula (NC). Preeclampsia labs were significant for
elevated LDH and protein/creatinine ratio (12.9). She received multiple antihypertensives to
correct elevated blood pressures, intravenous (IV) magnesium sulfate for seizure prophylaxis,
and betamethasone for fetal lung maturity. Chest radiography demonstrated diffuse focal
consolidation, patchy airspace opacities, and interstitial prominence consistent with COVID19 pneumonia. Fetal monitoring demonstrated category two fetal heart tracing. She was
admitted to labor and delivery (L&D) for induction of labor (IOL) for severe preeclampsia.
On L&D, her oxygen requirement increased to 6 liters saturating 92% with a respiratory
rate of 44-50 breaths/minute during the induction process and decision was made to proceed
with cesarean delivery for worsening maternal status. Patient received neuraxial anesthesia
and delivery was uncomplicated. Postoperatively, she was started on oral prednisone;
however, hydroxychloroquine was held due to prolonged QTc interval. Her oxygen
requirement increased to 8 liters saturating 90-92%. She was placed on 10L non-rebreather
mask and transferred to the intensive care unit (ICU). Her oxygen requirement was escalated
to high-flow NC, and she was intubated on post-operative day (POD)#0. She received 24
hours of postpartum magnesium sulfate for seizure prophylaxis and started on nifedipine for
persistent hypertension. Tracheal aspirate was negative for COVID-19. Ceftriaxone and
doxycycline were initiated due to concerns for concomitant community-acquired pneumonia.
She was extubated on POD#3 and was weaned to room air on POD#4. She was transferred to
the postpartum unit on POD#5. Neonatal course was uncomplicated and COVID testing was
negative.

Photos
Case 2. Severe Pre-Eclampsia
A 35 year old gravida 5 para 5 (history of twins) at 36 weeks and 4 days gestation presented
to L&D with worsening pelvic pain for one day. She denied shortness of breath, fevers, chills,
and gastrointestinal symptoms; however, reported a chronic cough during this pregnancy. She
worked in a nursing home, but stated no colleagues tested positive. She denied sick contacts.
She was febrile at 39.2oC, tachycardic at 140 beats/min, and hypertensive (150s/90s mmHg).
Her respiratory rate was 20 breaths/min, SpO2 90%., and placed on oxygen supplementation.
Fetal tachycardia (180-200 beats per minute) was noted on a non-stress test.
On exam, the patient had diminished breath sounds on the right lung. Chest radiography
demonstrated a central pulmonary infiltrative process consistent with pneumonia. COVID-19
and influenza nasopharyngeal swabs were obtained. Laboratory tests were remarkable for
elevated AST and LDH, lymphopenia, and proteinuria, meeting diagnostic criteria for
preeclampsia. Influenza result was negative.
Supportive care and antibiotics were initiated for suspected pneumonia while COVID results
were pending. On hospital day 2, IOL was recommended due to persistent category 2 fetal heart
tracing. Betamethasone was administered for fetal lung maturity. COVID-19 test resulted
positive 19 hours after collection, and she was started on oral hydroxychloroquine and IV
methylprednisolone. That evening, her respiratory status continued to worsen requiring 8L O2
NC. Blood pressures at this time were severe range requiring immediate release antihypertensive medication. Intravenous magnesium sulfate was initiated for seizure prophylaxis
in the setting of severe preeclampsia. She underwent an uncomplicated vacuum-assisted vaginal
delivery.
Magnesium sulfate was continued for 24 hours postpartum. Patient continued to wean off of
oxygen supplementation and was on room air by postpartum day (PPD)#2. Patient was
discharged home on PPD#3 in stable condition.
Neonatal course was complicated by respiratory distress. Apgars were 8 at one and five
minutes. Infant became tachypneic and cyanotic at two minutes of life, resuscitation was
performed, and the infant was transferred to the NICU on nasal cannula at 2 L/minute at FiO2
21-28%. Infant was started on ampicillin and gentamicin for sepsis prophylaxis. COVID-19
swabs were obtained on day of life 2 and 3 at 24 hours apart and were both negative. On day 3
of life, the infant was weaned to room air, antibiotics discontinued, and discharged home.

Case 3. Atypical HELLP Syndrome
A 35 year old gravida 8 para 7 (history of twins) female with six prior cesarean deliveries
was admitted at 36 weeks gestation for concern of preterm labor. She also reported feeling
unwell with associated abdominal pain, subjective fever, and body aches. She denied cough,
shortness of breath, gastrointestinal symptoms, or sick contacts.
On presentation, she was febrile to 38.3oC, blood pressure was 135/71 mmHg, heart rate 99
beats/min, and respiratory rate 22 breaths/min. Fetal tracing was category one. She was
admitted for suspicion of COVID-19 and to evaluate for concern of uterine rupture. COVID19 and influenza nasopharyngeal swabs were obtained. Laboratory results revealed elevated
AST and thrombocytopenia and at this time, she reported persistent headache. She was
diagnosed with atypical presentation of HELLP syndrome and was started on IV magnesium
sulfate. Given her persistent fevers and pending COVID-19 results, she was started on
gentamicin and clindamycin for presumptive diagnosis of chorioamnionitis. She underwent a
repeat cesarean delivery complicated by dense intra-abdominal adhesions and acute blood loss
anemia not requiring blood transfusion. Her postpartum course was complicated by persistent
fevers with progressive difficulty breathing and hypoxia requiring oxygen supplementation.
She required 3L O2 NC on POD#1. Magnesium sulfate was continued for 24 hours
postpartum. On POD#2, the COVID-19 test returned positive. Chest radiography revealed no
infiltrates. Computed tomography scan was negative for pulmonary embolism, but showed
concern for multifocal pneumonia. She was started on a five day course of
hydroxychloroquine. On POD#3, she was weaned off oxygen and saturating well on room air.
The AST increased from 37 to 76 IU/L, but remained stable during the remainder of her
hospital course. She was discharged on POD#5 in stable condition. Neonatal course was
uncomplicated and COVID testing was negative.

Image 1. Diffuse focal consolidation, patchy airspace
opacities, and insterstitial prominence consistent with
COVID-19 pneumonia for patient Case 1.

Image 2. Multifocal pneumonia seen on computed tomography for
patient in Case 3.

Discussion
• Magnesium sulfate reduces the risk of developing eclamptic seizures in the peripartum
period. [4-8]
• In the setting of COVID-19 viral pneumonia, treatment with magnesium sulfate may
worsen respiratory status and potentially increase the patient’s need for oxygen requirement
or mechanical ventilation.
• It is important to follow strict diagnostic criteria for severe preeclampsia, as risks for
worsening respiratory status in patients with COVID-19 can be prevented if they do not
require magnesium sulfate therapy
• Due to frequent capillary leak and decreased colloid oncotic pressure in preeclampsia,
excessive resuscitation may lead to elevation of pulmonary capillary wedge pressure and
increase risk of pulmonary edema
• Avoiding excessive fluid resuscitation in COVID-19 is important to minimize risk of
respiratory distress and help shorten duration of ventilation. [9-11]
• Recent meta-analysis of a combination of subtypes of coronavirus demonstrated an
increase risk for preterm birth, miscarriage, preeclampsia, cesarean birth, and perinatal
death. [12]
• A sub-analysis demonstrated only 1 of 12 patients with COVID-19 (13.55% [95% CI 1.236.0]) had coexisting preeclampsia.
• With the patients in our study, our presumption is that the diagnosis of severe preeclampsia
is superimposed upon the diagnosis of COVID-19, and could be one of several risk factors
placing the patient at higher risk of COVID-19 complications.
• As more studies regarding COVID-19 infection emerge, we would be able to obtain more
answers on its impact on pregnancy.
• In addition, larger studies are needed to explore new guidelines on preeclampsia diagnosis
and management in patients testing positive for COVID-19.
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